Physician profile
John Harris
NPI 1043360043
$15,412.48
in general payments reported to CMS, 2019-2025
57 companies · $2,353 in 2025
The $2,353 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,750 · 2020: $1,684 · 2021: $2,724 · 2022: $2,132 · 2023: $2,413 · 2024: $2,357 · 2025: $2,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,122.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,848.92 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,619.25 | 2019-2025 | Airsupra, Breztri, Bydureon |
| Amgen INC. | $1,397.12 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,285.46 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $894.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $856.27 | 2019-2025 | |
| Lilly USA, LLC | $840.26 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $764.71 | 2019-2025 | Xarelto, Invega Sustenna, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $561.43 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $498.99 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $437.41 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $393.01 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $382.83 | 2024-2025 | Zenpep |
| Astellas Pharma US INC | $332.43 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.63 | 2019-2025 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.